Navigation Links
World Renowned Scientist, Dr. Rongxiang Xu Speaks Out About Nobel Assembly Statement Claiming They Have Not Heard Of Him
Date:12/11/2012

LOS ANGELES, Dec. 11, 2012 /PRNewswire/ -- Dr. Rongxiang Xu, the founder of "human body regenerative restoration science" and a renowned life scientist and medical scientist, addresses The Nobel Assembly at Karolinska Institutet's initial statement regarding his lawsuit filing last week against the Academy citing Libel and unfair competition.

The Assembly provided a statement on their site: http://www.nobelprizemedicine.org/?p=3226 whereby they implied they have not heard of Dr. Xu, the founder of "human body regenerative restoration science" and a renowned life scientist and medical scientist. The Nobel Assembly's lack of acknowledgment is difficult to fathom considering the fact that Dr. Xu has a lifetime achievement in in situ regeneration research and is known worldwide as a pioneer in the field of regenerative medicine.

Furthermore, Dr. Xu was interviewed exclusively in 2003 by Sweden's Ministry of Education and Science and Sweden's national television SVT covering the topic of human body regeneration science.  It is also unlikely that The Nobel Assembly did not check US patents before they published statements on the Nobel Prize Awards.

Dr. Xu states, "I am not interested in who is awarded the Nobel Prize and I do not devalue the award.  I am concerned about the statements made by the Nobel Assembly.  I seek clarification regarding the issue of 'pluripotency by reprogramming' as it has been incorrectly stated and this can impact the safety of human life. I hope the Nobel Assembly can clarify what its 'pluripotency' means, is it completely conforming with the nature of human life? Or, is it the pluripotency of human cancer cells."

The Plaintiff, Dr. Xu is represented by the Ardent Law Group in California (case number 30-2012-00615804). For additional information, please contact Jane Westgate 336.608.4439, or Cheryl Riley 703.683.1798.


'/>"/>
SOURCE mebo-international.com
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Ansell y Comasec presentan Shared World of Innovation en ExpoProtection 2012
2. DOW Chemical at the World Drug Delivery & Formulation Summit 2013
3. Separation Design Group Launches Crowd-Funding Campaign for Worlds Smallest Oxygen Machine
4. SafeCode Drug Technologies Corporation Identifies the Technology Group to Commence and Develop the Worlds First Prototype for its Next Generation Application for Drug Safety Administration
5. SurgiQuest, Inc. Secures Additional $18.5 Million Funding to Fuel Worldwide Expansion and Commercialization Efforts
6. Ansell and Comasec Unveil Shared World of Innovation at ExpoProtection 2012
7. Premier Healthcare Alliance Awards 3-Year Group Purchasing Contract for Diaper and Adult Brief Waste Receptacles to Sinclair Worldwide
8. U.S. News & World Report and Pharmacy Times Introduce New Pharmacist-recommended Health Product Website
9. AVAC Report Finds That World is Already Falling Behind Pace to End AIDS Epidemic; Five Essential Actions Needed in 2013 to Avoid Historic Missed Opportunity
10. Philips transforms care to address the economic challenges faced by radiology departments and radiologists worldwide
11. Easy on the Stomach: ALCAT Worldwide Sponsors Successful Conference on Gut, Brain & Autoimmune Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
(Date:5/24/2016)... --   , ... Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung des ... guter , Reinigung des ... (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... der MORA-Studie der Phase III für NER1006 (1 ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... ... ... With over 60 percent of acute stroke survivors being left unable to ... in the rehabilitation process has steadily increased. Ekso Bionics had been working to help ... stroke. , Ekso Bionics has now received clearance from the U.S. Food and Drug ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research commissioned ... dogs straight off the grill. Of the 90 percent of Americans who say they ... hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving (9 ...
(Date:5/26/2016)... , ... May 26, 2016 , ... Connor Sports, ... basketball as a partner for the Tamika Catchings Legacy Tour that will ... industry leader in hardwood basketball surfaces in all forms and levels of the game, ...
Breaking Medicine News(10 mins):